HEALIONICS CORPORATION
Seattle, WA · Founded 2007 · CIK 0001413969 · Medtech · Private
Synthetic vascular graft with microporous sheath designed to reduce infection and stenosis in hemodialysis arteriovenous access
healionics.com →- Grants
- $10M
- 12 awards
- Sector median: 1
- Raised
- $13M
- 6 Form D · Dec 2025
- 9 months since last filing
- Contracts
- $1.1M
- 1 award · Defense
- #301 of 4531 in medtech
- Patents
- 18
- 5 granted · 13 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201020122014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $196,286 | |
| Private capital raised | Form D · SEC | $50,000 | |
| Federal contract | Department of Defense · Igf::ot::igf SBIR Phase I H141-009-0005 | $1,146,668 | |
| Federal grant | Department of Health and Human Services · Phase II · Infection and Thrombosis Resistant Needle-Free Hemodialysis Access Port and Graft Using STAR Biomaterials | $579,539 | |
| Federal grant | Department of Health and Human Services · Phase II · Biointegrating Dialysis Access Graft with Self Stabilizing Flow | $1,495,348 | |
| Federal grant | Department of Defense · Phase II · Biointegrated Synthetic Grafts for Reconstruction of Vascular Tissue | $999,690 | |
| Federal grant | Department of Health and Human Services · Phase II · Infection and Thrombosis Resistant Needle-Free Hemodialysis Access Port and Graft Using STAR Biomaterials | $595,657 | |
| Federal grant | Department of Health and Human Services · Phase II · Biointegrating Dialysis Access Graft with Self Stabilizing Flow | $633,578 | |
| Federal grant | Department of Health and Human Services · Phase II · Infection and Thrombosis Resistant Needle-Free Hemodialysis Access Port and Graft Using STAR Biomaterials | $142,446 | |
| Federal grant | Department of Health and Human Services · Phase II · Biointegrating Dialysis Access Graft with Self Stabilizing Flow | $280,674 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Study of an Extended-Patency Dialysis Access Graft | $440,339 | |
| Private capital raised | Form D · SEC | $1,048,068 | |
| Federal grant | Department of Health and Human Services · Phase I · Infection Resistant Hemodialysis Access Graft | $224,815 | |
| Federal grant | Department of Health and Human Services · Phase II · Product and Regulatory Development of a Needle-Free Hemodialysis Access Port | $2,980,952 | |
| Federal grant | Department of Health and Human Services · Phase II · Product and Regulatory Development of a Needle-Free Hemodialysis Access Port | $997,847 | |
| Private capital raised | Form D · SEC | $6,563,649 | |
| Federal grant | Department of Health and Human Services · Phase II · Product and Regulatory Development of a Needle-Free Hemodialysis Access Port | $984,472 | |
| Private capital raised | Form D · SEC | $2,684,000 | |
| Private capital raised | Form D · SEC | $1,964,221 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 298 | HYPOTHERMIA DEVICES INC | $1.2M | $11M |
| 299 | TESSARAE, LLC | $1.2M | — |
| 300 | Microscopy Innovations, LLC | $1.1M | $410K |
| 301 | HEALIONICS CORPORATION | $1.1M | $13M |
| 302 | SINTX TECHNOLOGIES, INC. | $1.1M | — |
| 303 | ISTO TECHNOLOGIES | $1.1M | $21M |
| 304 | HESKA CORP | $1.1M | $132M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Michel AlvarezDirector · Executive Officer
- Mike ConnollyDirector · Executive Officer
- Art CouryDirector
- Arthur CouryDirector
- Alan FuhrmanDirector
- Max MaginnessExecutive Officer
- Andrew MarshallDirector · Executive Officer
- Buddy RatnerDirector
- Ryan TakeuchiDirector
Patents
- Vascular Grafts And Method For Preserving Patency Of The Samegranted
- Injectable Porous Device For Treatment Of Dry And Wet Age-related Macular Degeneration Or Diabetic Retinopathygranted
- Corrugated Microporous Tissue Interface For Improved Performance And Infection Resistance Of Vascular Grafts And Other Implantable Devicesgranted
- Vascular Grafts And Method For Preserving Patency Of The Sameapplication
- Corrugated Microporous Tissue Interface For Improved Performance And Infection Resistance Of Vascular Grafts And Other Implantable Devicesgranted
- Vascular Grafts And Method For Preserving Patency Of The Sameapplication
- Implantable Medical Devices Having Microporous Surface Layers And Method For Reducing Foreign Body Response To The Samegranted
- Vascular Graft And Method For Preserving Patency Of The Sameapplication
- Vascular Graft And Method For Preserving Patency Of The Sameapplication
- Implantable Medical Devices Having Microporous Surface Layers And Method For Reducing Foreign Body Response To The Sameapplication
- Implantable Medical Devices Having Microporous Surface Layers And Method For Reducing Foreign Body Response To The Sameapplication
- Granules Of Porous Biocompatible Materialsapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.